New therapeutic strategies for the treatment of acute lymphoblastic leukaemia

Nature Reviews Drug Discovery

Volumn 6, Issue 2, 2007, Pages 149-165

  Pui, Ching Hon ^a,b   Jeha, Sima ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; EVOLTRA; FIBROBLAST GROWTH FACTOR RECEPTOR 3 INHIBITOR; FOLIC ACID ANTAGONIST; GAMMA SECRETASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; PEMETREXED; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; NUCLEOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGITATION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARACHNOIDITIS; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; LIPOSOMAL DELIVERY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; PAIN; PANCREATITIS; PERIPHERAL NEUROPATHY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; T LYMPHOCYTE; THROMBOSIS; TUMOR LYSIS SYNDROME; ACUTE LYMPHOCYTIC LEUKEMIA; GENETICS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NUCLEOSIDES;

EID: 33947588149     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2240     Document Type: Review

References (166)

1. Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178 (2006).
2. Oeffinger, K. C. & Hudson, M. M. Long-term complications following childhood and adolescent cancer: Foundations for providing risk-based health care for survivors. CA Cancer J. Clin. 54, 208-236 (2004).
3. Pui, C. H. et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med. 349 640-649 (2003).
4. Pui, C. H., Relling, M. V. & Downing, J. R. Acute lymphoblastic leukemia. N. Eng. J. Med. 350, 1535-1548 (2004).
5. Armstrong, S. A. & Look, A. T. Molecular genetics of acute lymphoblastic leukemia. J. Clin. Oncol. 23, 6306-6315 (2005).
6. LeBien, T. W. Fates of human B-cell precursors. Blood 96, 9-23 (2000).
7. Gill, J. et al. Thymic generation and regeneration. Immunol. Rev. 195, 28-50 (2003).
8. Pui, C. H. & Evans, W. E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605-615 (1998).
9. Pui, C. H., Campana, D. & Evans, W. E. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol. 2, 597-607 (2001).
10. Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1, 75-87 (2002).
11. Yeoh, E. J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1, 133-143 (2002).
12. Armstrong, S. A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet. 30, 41-47 (2002).
13. Haferlach, T. et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106, 1189-1198 (2005).
14. Lu. J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
15. Weng, A. P. et al. Activating mutations of NOTCH 1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
16. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell. 2, 103-112 (2002).
17. Krug, U., Ganser, A. & Koeffler, H. P. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21, 3475-3495 (2002).
18. Vousden, K. H. & Lu, X. Live or let die: The cell's response to p53. Nature Rev. Cancer 2, 594-604 (2002).
19. Avramis, V. I. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99, 1986-1994 (2002).
20. Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P. & Buchanan, G. R. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Croup Study. Blood 96, 1709-1715 (2000).
21. Hak, L. J. et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18, 1072-1077 (2004).
22. Moghrabi, A. et al. Results of the Dana-Farber Cancer Institute ALL Consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 26 Sep 2006 (doi: 10.1182/blood-2006-06-027714).
23. Bomgaars, L. et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J. Clin. Oncol. 22, 3916-3921 (2004).
24. Glantz, M. J. et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17, 3110-3116 (1999).
25. Jabbour, E. et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 5 Jan 2007 (doi:10.1182/ blood-2006-08-043646).
26. Offidani, M. et al. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukemia (ALL). Leuk. Lymphoma 46, 233-238 (2005).
27. Consoli, U. et al. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 88, 633-644 (1996).
28. Zou, Y., Priebe, W., Stephens, L. C. & Perez-Soler, R. Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity. Clin. Cancer Res. 1, 1369-1374 (1995).
29. Boman, N. L, Bally, M. B., Cullis, P. R., Mayer, L. D. & Webb, M. S. Encapsulation of vincristine in liposomes reduces its toxicity and improves its antitumor efficacy. J. Liposome Res. 5, 523-541 (1995).
30. Gelmon, K. A. et al. Phase I study of liposomal vincristine. J. Clin. Oncol. 17, 697-705 (1999).
31. Thomas, D. A. et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106, 120-127 (2006).
32. Walling, J. From methotrexate to premetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest. New Drugs 24, 37-77 (2006).
33. Sarris, A. H. et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J. Clin. Oncol. 20, 2876-2880 (2002).
34. O'Connor, O. et al. Pralatrexate (10-propargyl-10-deazaaminopterin (PDX), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity. Blood 106, 752a (2005).
35. Wang, E. S., Connor, O., She, Y., Zelenetz, A. D., Sirotnak, F. M. & Moore, M. A. Activity of a novel antifolate (PDX, 10-propargyl-10-deazaaminoptin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma 44, 1027-1035 (2003).
36. Toner. L. E. et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin. Cancer Res. 12, 924-932 (2006).
37. Villela, L. R., Stanford, B. L. & Shah. S. R. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 26, 641-654 (2006).
38. Parker, W. B. et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerase by its 5′-triphosphate. Cancer Res. 51, 2386-2394 (1991).
39. Santana, V. M. et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J. Clin. Oncol. 9, 416-422 (1991).
40. Kornblau, S. M. et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine+/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10 1563-1569 (1996).
41. Van Den Neste, E. et al. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann. Hematol. 76, 19-23 (1998).
42. Holowiecki, J. et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18, 989-997 (2004).
43. Vahdat, L. et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84, 3429-3434 (1994).
44. Warrell, R. P. Jr & Berman, E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 4, 74-79 (1986).
45. Montgomery, J. A., Shortnacy-Fowler, A. T., Clayton, S. D., Riordan, J. M. & Secrist, J. A. 3rd. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J. Med. Chem. 35, 397-401 (1992).
46. Avramis, V. I. & Plunkett, W. 2-fluoro-ATP: A toxic metabolite of 9-β-D-arabinosyl-2-fluoroadenine. Biochem. Biophys. Res. Comm. 113, 35-43 (1983).
47. Kantarjian, H. M. et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 21, 1167-1173 (2003).
48. Kantarjian, H. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379-2386 (2003).
49. Jeha, S. et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103, 784-789 (2004).
50. Jeha, S. et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol. 24, 1917-1923 (2006).
51. Giblett, E. R., Ammann, A. J., Wara, D. W., Sandman, R. & Diamond, L. K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1, 1010-1013 (1975).
52. Cohen. A.. Lee, J. W. & Gelfand, E. W. Selective toxicity of deoxyguanosine and arabinosylguanine for T-leukemic cells. Blood 61, 660-666 (1983).
53. Reist, E. J. & Goodman, L. Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry 3, 15-18 (1964).
54. Kurtzberg, J. et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 23, 3396-3403 (2005).
55. Berg, S. L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J. Clin. Oncol. 23 3376-3382 (2005).
56. Miles, R. W., Tyler P. C., Furneaux, R. H., Bagdassarian, C. K. & Schramm, V. L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 37, 8615-8641 (1998).
57. Banda, S. et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent. Int. Immunopharm. 1, 1199-1210 (2001).
58. Gandhi, V. et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106, 4253-4260 (2005).
59. Schulz, H. et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematol. 89, 753-754 (2004).
60. Stasi, R., Pagano, A., Stipa, E. & Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952-957 (2001).
61. Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673-2677 (2002).
62. Coiffier. B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
63. Thomas, D. A. et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106, 1569-1580 (2006).
64. Thomas, D. A. et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 102, 880a (2003).
65. Jeha, S. et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108, 3302-3304 (2006).
66. Dillman, R. O. et al. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin. Exp. Med. 6, 1-12 (2006).
67. Leonard, J. P. et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. 10, 5327-5334 (2004).
68. Stein, R. et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10, 2868-2878 (2004).
69. Leonard, J. P. et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 5044-5051 (2005).
70. Linden, O. et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin. Cancer Res. 11, 5215-5222 (2005).
71. Uckun, F. M. et al. Detailed studies on expression and function of CD 19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD 19 immunotoxins. Blood 71, 13-29 (1988).
72. Goulet, A. C. et al. Conjugation of blocked ricin to an anti-CD 19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD 19 internalization. Blood 90, 2364-2375 (1997).
73. Stone, M. J. et al. A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88, 1188-1197 (1996).
74. Bae, J., Martinson, J. A. & Klingemann, H. G. Identification of CD 19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin. Cancer Res. 11, 1629-1638 (2005).
75. Vallera, D. A. et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD 19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin. Cancer Res. 11, 3879-3888 (2005).
76. Gilleece, M. H. & Dexter, T. M. Effect of Campath-1 H antibody on human hematopoietic progenitors in vitro. Blood 82, 807-812 (1993).
77. Piccaluga, P. P. et al. Anti-leukemic and anti-GVHD effects of Campath-1 H in acute lymphoblatic leukemia relapsed after stem-cell transplantation. Leuk. Lymphoma 45, 731-733 (2004).
78. Laporte, J. P. et al. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 18, 1557-1558 (2004).
79. Tibes, R. et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106, 2645-2651 (2006).
80. Stock, W. et al. Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: A phase I/II study from the Cancer and Leukemia Group B (CALGB 10102). Blood 106, 46a (2005).
81. Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244-3254 (2001).
82. + acute myeloid leukemia. Blood 106, 1183-1188 (2005).
83. Lo-Coco, F. et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104, 1995-1999 (2004).
84. Golay, J. et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128, 310-317 (2005).
85. Zwaan, C. M. et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: First clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 17, 468-470 (2003).
86. Cotter, M., Rooney, S., O'Marcaigh, A. & Smith, O. P. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br. J. Haematol. 122, 687-688 (2003).
87. Balduzzi, A. et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4; 11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 17, 2247-2248 (2003).
88. Jedama, I. et al. Internalization and cell cycle-dependent killing of leukemia cells by gemtuzumab ozogamicin: Rational for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18 316-325 (2004).
89. Graux, C. et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature Genet. 36, 1084-1089 (2004).
90. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
91. Champagne, M. A. et al. Imatinib mesylate (ST1571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 104, 2655-2660 (2004).
92. Thomas, D. A. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396-4407 (2004).
93. Towatari, M. et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104, 3507-3512 (2004).
94. Rea, D. et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20, 400-403 (2006).
95. Lee, S. et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105, 3449-3457 (2005).
96. + ALL). Blood 106, 458-463 (2005).
97. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
98. Roche-Lestienne, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
99. O'Hare, T. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65, 4500-4505 (2005).
100. Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N. Engl. J. Med. 354, 2542-2551 (2006).
101. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N. Engl. J. Med. 354, 2551-2541 (2006).
102. Quintas-Cardama, A. et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogeneous leukemia after imatinib and nilotinib (AMN 107) therapy failure. Blood 21 Sep 2006 (doi: 10.1182/blood-2006-07-035493).
103. Giles, F. J. et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T3151 BCR-ABL mutation. Blood 21 Sep 2006 (doi: 10.1182/blood-2006-05-025049).
104. Lee, B. H. et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24, 7882-7892 (2005).
105. Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669-3676 (2004).
106. Fiedler, W. et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 986-993 (2005).
107. Armstrong, S. A. et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173-183 (2003).
108. + adult acute lymphoid leukaemia. Br. J. Haematol. 130, 43-50 (2005).
109. Brown, P. et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105, 812-820 (2005).
110. Levis, M., Pham, R., Smith, B. D. & Small, D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: Sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104, 1145-1150 (2004).
111. Piloto, O. et al. IMC-EB 10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 66, 4843-4851 (2006).
112. Hoover, R. R., Mahon, F. X., Melo, J. V. & Daley, G. Q. Overcoming ST1571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100, 1068-1071 (2002).
113. Kurzrock, R. et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22, 1287-1292 (2004).
114. Borthakur, G. et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106, 346-352 (2006).
115. Klp2, and p15, has prognostic value in adult acute lymphoblastic leukemia independently of its methylated status. J. Clin. Oncol. 23, 3932-3939 (2005).
116. Zheng, S. et al. Hypermethylation of the 5′ CpG island ofthe FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer Res. 64, 2000-2006 (2004).
117. Stam, R. W. et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 20, 264-271 (2006).
118. Christman, J. K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483-5495 (2002).
119. Wijermans, P. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956-962 (2000).
120. Klisovic, M. I. et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350-358 (2003).
121. Messinger, Y, Reaman, G. H., EK, O. & Uckun, F. M. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. Leuk. Lymphoma 33, 289-293 (1999).
122. Seiter, K. et al. Phase I study of temozolomide in relapsed/ refractory acute leukemia. J. Clin. Oncol. 20, 3249-3253 (2002).
123. Khan, R. B., Raizer, J. J., Malkin, M. G., Bazylewicz, K. A. & Abrey, L. E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 4, 39-43 (2002).
124. Sakajiri, S. et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 33, 53-61 (2005).
125. Byrd, J. C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959-967 (2005).
126. Inoue, S. et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11, S193-S206 (2004).
127. Nimmanapalli, R., Fuino, L, Stobaugh, C., Richon, V. & Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101, 3236-3239 (2003).
128. Batova, A. et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100, 3319-3324 (2002).
129. Cutts, S. M., Rephael, A., Nudelman, A., Hmelnitsky, I. & Phillips, D. R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 61, 8194-8202 (2001).
130. Avellino, R. et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106, 1400-1406 (2005).
131. Teachey, D. T. et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149-1155 (2006).
132. Pear, W. S. et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183, 2283-2291 (1996).
133. Fekete, M. R., McBride, W. H. & Pajonk F. Anthracyclines, proteasome activity and multi-drug resistance. BMC Cancer 5, 114 (2005).
134. Cortes, J. et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10, 3371-3376 (2004).
135. Sutheesophon, K. et al. Histone deacetylase inhibitor depsipetide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 115, 78-90 (2006).
136. Arguello, F. et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-2490 (1998).
137. Almenara, J., Rosato, R. & Grant, S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16, 1331-1343 (2002).
138. Dasmahapatra, G., Almenara, J. A. & Grant, S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol. Pharmacol. 69 288-298 (2006).
139. Rosato, R. R., Dai, Y., Almenara, J. A., Maggio, S. C. & Grant, S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 18 1780-1788 (2004).
140. Yu, C., Krystal, G., Dent, P. & Grant, S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin. Cancer Res. 8, 2976-2984 (2002).
141. Karp, J. E. et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res. 11, 8403-8412 (2005).
142. Banker, D. E. et al. The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin. Cancer Res. 4, 3051-3062 (1998).
143. Campos, L. et al. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 10, 434-438 (1996).
144. Hogarth, L. A. & Hall, A. G. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 93, 2671-2678 (1999).
145. Tauchi, T. et al. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res. 9, 4267-4273 (2003).
146. Marcucci, G. et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101, 425-432 (2003).
147. Gorre. M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N. & Sawyers, C. L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100, 3041-3044 (2002).
148. Crespo, M. et al. ZAP-70 expression in normal pro/pre B cells, mature B cells and in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 12, 726-734 (2006).
149. + cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67, 1166-1176 (2005).
150. Pelicano, H. et al. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 20, 610-619 (2006).
151. George, P. et al. Combination of the histone deacetylase inhibitor LBH589 and the HSP90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768-1776 (2005).
152. George, P. et al. Cotreatment with 17-allylaminodemethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 64, 3645-3652 (2004).
153. Hawkins, L. M., Jayanthan, A. A. & Narendran, A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr. Res. 57, 430-437 (2005).
154. Mesa, R. et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106, 318-327 (2005).
155. Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316-323 (2004).
156. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
157. Sawyers C. Targeted cancer therapy. Nature 432, 294-297 (2004).
158. Karagiannis, T. C. & El-Osta, A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther. 12, 787-795 (2005).
159. Thomas, M., Gessner, A., Vornlocher, H. P., Hadwiger, P., Greil, J. & Heidenreich, O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells, Blood 106, 3559-3566 (2005).
160. Lang, P. et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood, 103, 3982-3985 (2004).
161. Blair, A., Goulden, N. J., Libri, N. A., Oakhill, A. & Pamphilon, D. H. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev. 19, 289-300 (2005).
162. Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376-383 (2005).
163. Sparreboom, A., Baker, S. D. & Verweij, J. Paclitaxel repackaged in an albumin-stabilized nanoparticle: Handy or just a dandy? J. Clin. Oncol. 23, 7765-7767 (2005).
164. Cheok, M. H. & Evans, W. E. Acute lymphoblastic leukaemia: A model for the pharmacogenomics of cancer therapy. Nature Rev. Cancer 6 117-129 (2006).
165. Rocha, J. C. et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105, 4752-4758 (2005).
166. Cheng, O., Yang, W., Raimondi, S. C., Pui, C. H., Relling, M. V. & Evans, W. E. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nature Genet. 37, 878-882 (2005).